Get started
Author

S.E. Kim

LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
2022 · M. Allaf, S.E. Kim, et al. · Annals of Oncology · 77
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial
2026 · Glenn J. Hanna, Tulika R. Gupta, et al. · Nature Communications · 6
PDF
394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
2024 · P. Tarantino, S.E. Kim, et al. · Annals of Oncology · 5
Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial
2026 · Jonathan So, Alexander D. Droznin, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
PDF
Abstract P1-01-09: Clinicopathological features, treatment patterns and outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer compared with sporadic tumors in young women: a matched analysis
2025 · Stefania Morganti, Se E. Kim, et al. · Clinical Cancer Research
285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study
2023 · S. Morganti, S.E. Kim, et al. · Annals of Oncology
PDF
P-142 Severity of Malnutrition Status of Gastrointestinal Cancer: Nutritional Screening and Assessment Registry in Korean Gastroenterointestinal Cancer Patients
2015 · E.S. Kim, G.A. Song, et al. · Annals of Oncology
Works count: 7
Citation count: 90
H-index: 3
I10-index: 1
Year
Topic
Type